AAT-AD/PDTM 2018 FORUM DISCUSSIONS
These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in "hottest" research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of AD and PD therapeutics.
Each forum will be 60 minutes moderated discuss ion with maximum 3 minutes introduction statement from each participant followed by questions from the audience submitted via Ask the Speaker function in the mobile APP and introduced to the discussion by the moderator. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.
Join the debate in:
FORUM DISCUSSION 1: FORUM ON TRANSLATIONAL RESEARCH IN DRUG DISCOVERY FOR AD
THURSDAY, MARCH 15, 2018; 15:40 - 16:40: SALA 500
Co-Moderators: Ezio Giacobini (University of Geneva Medical School Hospitals) Switzerland and Jeffrey Cummings (Cleveland Clinic Lou Ruvo Center for Brain Health), USA
Participants: Amos D. Korczyn (Tel Aviv University), Israel / Andreas Muhs (AC Immune), Switzerland /Jeff Sevigny (Roche), Switzerland / Robert Davis, (Intracellular Therapies), USA /Nadeem Sarwar (Eisai), USA
FORUM DISCUSSION 2: AD PHASE III CLINICAL TRIALS
FRIDAY, MARCH 16, 2018; 14:45-15:45: SALA 500
Co-Moderators: Bengt Winblad (Karolinska Institute) , Sweden and Manfred Windisch (NeuroScios), Austria
Participants: Rachelle Doody (Roche), Switzerland / Michael Irizarry (Eli Lilly), USA/ Philipp von Rosenstiel (Biogen), USA/ Lynn Kramer (Eisai),USA
FORUM DISCUSSION 3: FORUM ON NOVEL APPROACHES TO DISEASE-MODIFYING THERAPIES OF PD & LBD
SATURDAY, MARCH 17, 2018; 14:00 - 15:00: SALA 500
Moderator: Jamie Eberling, (Michael J Fox Foundation), USA
Participants: Gene Kinney (Prothena), USA/ Jesse Cederbaum (Biogen), USA/ Walter Koroshetz (NINDS), USA/ Johan Luthman (Eisai), USA